Shares of Organogenesis Holdings Inc (NASDAQ:ORGO) have received a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.80.
A number of analysts have commented on the company. BTIG Research reissued a “hold” rating on shares of Accelerate Diagnostics in a report on Sunday, May 12th. Zacks Investment Research upgraded General Moly from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th. CIBC initiated coverage on Organogenesis in a research report on Wednesday, April 17th. They set an “outperform” rating and a $11.00 target price on the stock. Oppenheimer set a $119.00 target price on American Express and gave the company a “buy” rating in a research report on Wednesday, April 17th. Finally, SunTrust Banks lowered their target price on Unisys to $17.00 and set a “buy” rating on the stock in a research report on Thursday, April 11th.
An institutional investor recently bought a new position in Organogenesis stock. Moors & Cabot Inc. acquired a new position in shares of Organogenesis Holdings Inc (NASDAQ:ORGO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 91,350 shares of the company’s stock, valued at approximately $694,000. Moors & Cabot Inc. owned about 0.10% of Organogenesis at the end of the most recent reporting period. Institutional investors and hedge funds own 0.89% of the company’s stock.
NASDAQ:ORGO traded down $0.05 during trading hours on Friday, reaching $6.15. 24,444 shares of the company traded hands, compared to its average volume of 87,798. The firm has a 50-day moving average price of $7.29. Organogenesis has a 1 year low of $6.08 and a 1 year high of $310.90. The company has a current ratio of 1.07, a quick ratio of 0.87 and a debt-to-equity ratio of 1.05.
Organogenesis (NASDAQ:ORGO) last posted its earnings results on Friday, May 10th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.05). The business had revenue of $57.12 million during the quarter, compared to analyst estimates of $55.12 million. As a group, equities research analysts predict that Organogenesis will post -0.47 EPS for the current year.
Organogenesis Company Profile
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Recommended Story: Why does a company issue an IPO?
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.